Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands

Clinical Therapeutics

Volumn 39, Issue 2, 2017, Pages 288-302.e4

  de Jong, Lisa A ^a   Dvortsin, Evgeni ^a   Janssen, Kristel J ^b   Postma, Maarten J ^a,c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b BRISTOL MYERS SQUIBB   (United States)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

apixaban; cost effectiveness; direct oral anticoagulant; venous thromboembolism

Indexed keywords

ACENOCOUMAROL; APIXABAN; NADROPARIN; PHENPROCOUMON; WARFARIN; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; FEMALE; HEALTH CARE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MARKOV CHAIN; MIDDLE AGED; NETHERLANDS; OUTCOME ASSESSMENT; POSTTHROMBOSIS SYNDROME; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; THROMBOSIS PREVENTION; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS;

ANTICOAGULANTS; COST-BENEFIT ANALYSIS; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PYRAZOLES; PYRIDONES; QUALITY-ADJUSTED LIFE YEARS; VENOUS THROMBOEMBOLISM;

EID: 85011005095     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.12.012     Document Type: Article

References (46)

1. 1 Oudega, R., Van Weert, H., Stoffers, H.E.J.H., et al. NHG-Standaard Diepe veneuze trombose en longembolie (eerste herziening). NHG-werkgroep Diepe veneuze trombose en longembolie. Huisarts Wet 58 (2015), 26–35.
2. 2 Federation Dutch Thrombotic Services (FNT). Samenvatting Medische Jaarverslagen 2014. http://www.fnt.nl/media/docs/FNT_Samenvatting_Medisch_JV_2014.pdf. [Accessed September 2015].
3. 3 Kwaliteitsinstituut voor de Gezondheidszorg CBO i.s.m.Nederlands Huisartsen Genootschap NHG, Richtlijn Diagnostiek, Preventie, en Behandeling van Veneuze Trombo-embolie en Secundaire Preventie Arteriële Trombose. 2008, CBO, Utrecht.
4. 4 Prandoni, P., Lensing, A.W., Cogo, A., et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125 (1996), 1–7.
5. 5 Gage, B.F., Cardinalli, A.B., Owens, D.K., The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 156 (1996), 1829–1836.
6. 6 Goldhaber, S.Z., Visani, L., De Rosa, M., Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 353 (1999), 1386–1389.
7. 7 Werth, S., Breslin, T., Niainle, F., Beyer-Westendorf, J., Bleeding risk, management and outcome in patients receiving non-VKA oral anticoagulants (NOACs). Am J Cardiovasc Drugs 15 (2015), 235–242.
8. 8 Agnelli, G., Buller, H.R., Cohen, A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369 (2013), 799–808.
9. 9 Agnelli, G., Buller, H.R., Cohen, A., et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368 (2013), 699–708.
10. 10 Instructions for costs research in Dutch Health settings. 2016. https://www.zorginstituutnederland.nl/over-ons/publicaties/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg. [Accessed September 2015].
11. st edition, 2006, Oxford University Press.
12. 12 Stevanovic, J., de Jong, L.A., Kappelhoff, B.S., et al. Dabigatran for the treatment and secondary prevention of venous thromboembolism; a cost-effectiveness analysis for the Netherlands. PlosOne, 11, 2016, e0163550.
13. 13 Prandoni, P., Noventa, F., Ghirarduzzi, A., et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 92 (2007), 199–205.
14. 14 Linkins, L., O׳Donnell, M., Julian, J.A., Kearon, C., Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy. J Thromb Haemost 8 (2010), 2201–2207.
15. 15 Ariesen, M., Claus, S., Rinkel, G., Algra, A., Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke 34 (2003), 2060–2065.
16. 16 Miniati, M., Monti, S., Bottai, M., et al. Survival and restoration of pulmonary perfusion in a long-term follow-up of patients after acute pulmonary embolism. Medicine 85 (2006), 253–262.
17. 17 Prandoni, P., Villalta, S., Bagatella, P., et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 82 (1997), 423–428.
18. 18 Flinterman, L.E., van Hylckama Vlieg, A., Cannegieter, S.C., Rosendaal, F.R., Long-term survival in a large cohort of patients with venous thrombosis: incidence and predictors. PLoS Med, 9, 2012, e1001155.
19. 19 Prandoni, P., Trujillo-Santos, J., Sanchez-Cantalejo, E., et al. Major bleeding as a predictor of mortality in patients with venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost 8 (2010), 2575–2577.
20. 20 Ng, A.C., Chung, T, Yong, A.S., et al. Long-term cardiovascular and non- cardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism. Circ Cardiovasc Qual Outcomes 4 (2011), 122–128.
21. 21 Statistics Netherlands website. Life-expectancy; gender and age, from 1950 (per year). http://statline.cbs.nl/Statweb/publication/?DM=SLNL&PA=37360ned&D1=0&D2=a&D3=20-99&D4=l&HDR=G1,T&STB=G2,G3&VW=T. [Accessed October 2015].
22. 22 Kind, P., Dolan, P., Gudex, C., Williams, A., Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 316 (1998), 736–741.
23. 23 Locadia, M., Bossuyt, P.M., Stalmeier, P.F., et al. Treatment of venous thromboembolism with vitamin K antagonists: patients׳ health state valuations and treatment preferences. Thromb Haemost 92 (2004), 1336–1341.
24. 24 Ghofrani, H.A., D׳Armini, A.M., Grimminger, F., et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369 (2013), 319–329.
25. 25 Sullivan, P.W., Slejko, J.F., Sculpher, M.J., Ghushchyan, V., Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making 31 (2011), 800–804.
26. 26 Lenert, L.A., Soetikno, R.M., Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc 4 (1997), 49–56.
27. 27 National Institute of Health and Care Excellence (NICE). Venous thromboembolism: reducing the risk for patients in hospital, 2010 NICE CG92.
28. 28 Hogg, K., Kimpton, M., Carrier, M., et al. Estimating quality of life in acute venous thrombosis. JAMA Intern Med 173 (2013), 1067–1072.
29. 29 Z-index. www.medicijnkosten.nl. [Accessed September 2015].
30. 30 NZA tarievenlijst. Version 2012.
31. 31 Stevanović, J., Pompen, M., Le, H.H., et al. Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands. PLoS ONE, 9, 2014, e103974.
32. 32 National Institute for Health and Care Excellence (NICE). Final appraisal determination – Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism. Issue date: April 2013. https://www.nice.org.uk/guidance/TA287/documents/pulmonary-embolism-acute-treatment-vte-prevention-rivaroxaban-final-appraisal-determination-document2. [Accessed September 2015].
33. 33 National Institute for Health and Care Excellence (NICE). Final appraisal determination – Final appraisal determination – Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. Issue date: May 2013. https://www.nice.org.uk/guidance/ta261/resources/venous-thromboembolism-treatment-and-long-term-secondary-prevention-rivaroxaban-final-appraisal-determination-guidance2. [Accessed September 2015].
34. 34 Ten Cate‐Hoek, A., Toll, D., Büller, H., et al. Cost‐effectiveness of ruling out deep venous thrombosis in primary care versus care as usual. J Thromb Haemost 7 (2009), 2042–2049.
35. 35 Hakkaart-van Roijen, L., Tan, S.S., Bouwmans, C.A.M., Handleiding voor kostenonderzoek. iMTA geactualiseerde versie Dutch Cost Manual, 2010.
36. 36 Den Haag/Heerlen. Central Institute of Statistics Web site. http://statline.cbs.nl. [Accessed September 2015].
37. 37 Guanella, R., Ducret, T., Johri, M., et al. Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: a prospective evaluation. J Thromb Haemost 9 (2011), 2397–2405.
38. 38 Canadian Drug Expert Committee (CDEC). Apixaban for the treatment of venous thromboembolic events (VTE) (deep vein thrombosis [DVT] and pulmonary embolism [PE]) and prevention of recurrent DVT and PE, for a duration of up to six months. Issue date: April 2015. Available from: https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_SR0397_Eliquis-VTE_May-11-15.pdf. [Accessed October 2015].
39. 39 GSK Professionals. Fraxodi dosage advice, prevention and treatment. http://professionals.gsk.nl/content/dam/Health/nl_NL/HCP_Home/therapiegebieden/Trombose/documents/nl-trombose-dosagecard.pdf. [Accessed September 2015].
40. 40 Dutch Federation for Thrombotic Services. 2010. http://www.fnt.nl/media/docs/jaarverslagen/Jaarverslag_FNT_Medisch_2010.pdf. [Accessed September 2015].
41. 41 Key Opinion Leader: Medical professor in one of the University Medical Centers in the Netherlands with over 20 years experience in the diagnosis and treatment of venous thromboembolism.
42. 42 Inflation Statistics Netherlands. http://statline.cbs.nl/Statweb/publication/?DM=SLNL&PA=70936NED&D1=0&D2=662,675,682-684&HDR=T&STB=G1&VW=T. [Accessed October 2015].
43. 43 NZA, Version Dutch guidelines for pharmaco-economic research, 2015.
44. 44 Quon, P., Le, H.H., Raymond, V., et al. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada. J Med Econ 19 (2016), 557–567.
45. 45 Amin, A., Jing, Y., Trocio, J., et al. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients. J Med Econ 17 (2014), 763–770.
46. 46 Jugrin, A.V., Hösel, V., Ustyugova, A., et al. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting. J Med Econ 19 (2015), 1–10.